MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; degenerative diseases; neurodegenerative diseases, such as amyotrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. MeiraGTx Holdings plc was incorporated in 2015 and is based in New York, New York.
Earnings for MeiraGTx Holdings plc (MGTX)
Earnings in 2023 (TTM): $-84,027,000
According to MeiraGTx Holdings plc's latest financial reports the company's current earnings (TTM) are $-84,027,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of MeiraGTx Holdings plc
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-84,027,000 | $-84,027,000 |
| 2022 | $-129,615,000 | $-142,875,000 |
| 2021 | $-79,561,000 | $-71,976,000 |
| 2020 | $-57,992,004 | $-53,959,581 |
| 2019 | $-54,746,235 | $-52,556,287 |
| 2018 | $-83,340,265 | $-82,865,874 |
| 2017 | $-31,044,535 | $-31,044,535 |
| 2016 | $-19,792,276 | $-19,486,393 |